Nivolumab in combinazione con chemio-immunoterapia per il trattamento del linfoma primitivo a cellule B del mediastino di nuova diagnosi
Uno studio randomizzato di fase 3 su nivolumab (NSC# 748726) in combinazione con chemio-immunoterapia per il trattamento del linfoma primitivo a cellule B del mediastino di nuova diagnosi
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Panoramica dello studio
Stato
Intervento / Trattamento
- Droga: Cyclophosphamide
- Droga: Doxorubicin Hydrochloride
- Droga: Prednisone
- Biologico: Rituximab
- Droga: Vincristine Sulfate
- Procedura: Echocardiography Test
- Biologico: Nivolumab
- Procedura: Computed Tomography
- Procedura: Positron Emission Tomography
- Droga: Etoposide Phosphate
- Biologico: Filgrastim
- Procedura: Bone Marrow Aspiration
- Procedura: Bone Marrow Biopsy
- Radiazione: Radiation Therapy
- Droga: Prednisolone
- Biologico: Pegfilgrastim
- Procedura: Lumbar Puncture
- Procedura: Biospecimen Collection
- Biologico: Rituximab and Hyaluronidase Human
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To determine if nivolumab + chemo-immunotherapy results in a superior long term progression-free survival (PFS) (events defined as disease progression confirmed by central review or death) when compared with chemo-immunotherapy alone in patients with newly diagnosed primary mediastinal B-cell lymphoma.
SECONDARY OBJECTIVES:
I. To compare the rates of "efficacy-related event-free survival (EFS)" (eEFS) (events defined as progression, change in therapy due to finding that led to concern about efficacy, biopsy + disease after 6 cycles of therapy, or death) between chemo-immunotherapy alone and chemo-immunotherapy + nivolumab in patients with newly diagnosed PMBCL.
II. To compare the rates of "therapy-related EFS" (tEFS) (events defined as relapse/progression, change in therapy for any reason, biopsy + disease after 6 cycles of therapy, secondary malignancy [SMN] or death) between chemo-immunotherapy alone and chemo-immunotherapy + nivolumab in patients with newly diagnosed PMBCL.
III. To compare the rates of overall survival (OS) between chemo-immunotherapy alone and chemo-immunotherapy + nivolumab in patients with newly diagnosed PMBCL.
IV. To establish the rate of a positive positron emission tomography (PET)-computed tomography (CT) (defined as Deauville score 4 or 5) at the completion of 6 cycles of nivolumab + rituximab (R)- cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/dose-adjusted (DA)-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH)-R and R-CHOP/DA-EPOCH-R in patients with newly diagnosed PMBCL and evaluate the prognostic significance of such a finding.
EXPLORATORY OBJECTIVES:
I. To bank radiology images for further studies. II. To bank specimens for future correlative studies. III. Characterize the immune profile of patients treated with nivolumab + chemo-immunotherapy to identify markers predictive of response.
IV. Define the rate of complete response at the completion of initial planned therapy.
OUTLINE: Patients are randomly assigned to backbone therapy or backbone therapy + nivolumab within each of 6 strata. The strata are determined by physician's choice of backbone (DA-EPOCH-R versus [vs.] R-CHOP vs. R-CHOP + RT) and whether or not the patient had 1 prior cycle of therapy.
ARM A (DA-EPOCH-R): Patients receive prednisone or prednisolone orally (PO) once daily (QD) on days 1-5 and rituximab intravenously (IV) or rituximab and hyaluronidase human subcutaneously (SC) over 5 minutes on day 1 or 5. Patients also receive etoposide phosphate, doxorubicin hydrochloride, and vincristine sulfate IV over 96 hours on days 1-4 and cyclophosphamide IV over 30-60 minutes on day 5. Beginning 24-72 hours after completing cyclophosphamide, patients receive filgrastim or pegylated filgrastim SC daily until absolute neutrophil count (ANC) is >= 500/uL after the expected nadir. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) during screening and as clinically indicated and a lumbar puncture (LP) for cerebral spinal fluid (CSF) collection optionally during screening. Patients also undergo computed tomography (CT) or positron emission tomography (PET)/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM B (DA-EPOCH-R + NIVOLUMAB): Patients receive treatment as in Arm A. Patients also receive nivolumab IV over 30 minutes on day 1. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM C (R-CHOP): Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 1-15 minutes or up to 60 minutes, and vincristine sulfate IV over 1 or up to 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM D (R-CHOP + NIVOLUMAB): Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM E (R-CHOP + RADIOTHERAPY): Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM F (R-CHOP + RADIOTHERAPY + NIVOLUMAB): Patients receive treatment as in Arm D. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
After completion of study treatment, patients are followed up every 3 months for year 1, every 6 months for years 2-3, and annually thereafter.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australia, 2310
- John Hunter Children's Hospital
-
Westmead, New South Wales, Australia, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Queensland Children's Hospital
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australia, 6009
- Perth Children's Hospital
-
-
-
-
-
Québec, Canada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Janeway Child Health Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
London, Ontario, Canada, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
-
-
-
Caguas, Porto Rico, 00726
- HIMA San Pablo Oncologic Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Stati Uniti, 36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Stati Uniti, 85202
- Banner Children's at Desert
-
Tucson, Arizona, Stati Uniti, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Costa Mesa, California, Stati Uniti, 92627
- UC Irvine Health Cancer Center-Newport
-
Downey, California, Stati Uniti, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Stati Uniti, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Stati Uniti, 92618
- City of Hope at Irvine Lennar
-
Irvine, California, Stati Uniti, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Loma Linda, California, Stati Uniti, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Stati Uniti, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Stati Uniti, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Stati Uniti, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, Stati Uniti, 90095
- Mattel Children's Hospital UCLA
-
Madera, California, Stati Uniti, 93636
- Valley Children's Hospital
-
Oakland, California, Stati Uniti, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Stati Uniti, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Stati Uniti, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Stati Uniti, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Stati Uniti, 92123
- Rady Children's Hospital - San Diego
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Stati Uniti, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06106
- Connecticut Children's Medical Center
-
-
Delaware
-
Wilmington, Delaware, Stati Uniti, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Stati Uniti, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Stati Uniti, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Stati Uniti, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Stati Uniti, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Stati Uniti, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Stati Uniti, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Stati Uniti, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, Stati Uniti, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Stati Uniti, 32806
- Arnold Palmer Hospital for Children
-
St. Petersburg, Florida, Stati Uniti, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Stati Uniti, 33606
- Tampa General Hospital
-
Tampa, Florida, Stati Uniti, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Stati Uniti, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Stati Uniti, 30308
- Emory Proton Therapy Center
-
Atlanta, Georgia, Stati Uniti, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Savannah, Georgia, Stati Uniti, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Aurora, Illinois, Stati Uniti, 60504
- Rush-Copley Medical Center
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Lurie Children's Hospital-Chicago
-
Danville, Illinois, Stati Uniti, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Stati Uniti, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Stati Uniti, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Stati Uniti, 60134
- Northwestern Medicine Cancer Center Delnor
-
Lake Forest, Illinois, Stati Uniti, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Stati Uniti, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Stati Uniti, 60153
- Loyola University Medical Center
-
O'Fallon, Illinois, Stati Uniti, 62269
- HSHS Saint Elizabeth's Hospital
-
Oak Lawn, Illinois, Stati Uniti, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, Stati Uniti, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, Stati Uniti, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Stati Uniti, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stati Uniti, 62702
- Springfield Clinic
-
Springfield, Illinois, Stati Uniti, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Stati Uniti, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Riley Hospital for Children
-
Richmond, Indiana, Stati Uniti, 47374
- Reid Health
-
-
Iowa
-
Ankeny, Iowa, Stati Uniti, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Stati Uniti, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Stati Uniti, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stati Uniti, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, Stati Uniti, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Sioux City, Iowa, Stati Uniti, 51101
- Siouxland Regional Cancer Center
-
Waukee, Iowa, Stati Uniti, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kansas
-
Wichita, Kansas, Stati Uniti, 67214
- Wesley Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Stati Uniti, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Stati Uniti, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Stati Uniti, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Stati Uniti, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Stati Uniti, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Stati Uniti, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Stati Uniti, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Stati Uniti, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Stati Uniti, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Stati Uniti, 48201
- Children's Hospital of Michigan
-
East Lansing, Michigan, Stati Uniti, 48823
- Michigan State University
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Bronson Methodist Hospital
-
Niles, Michigan, Stati Uniti, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Royal Oak, Michigan, Stati Uniti, 48073
- Corewell Health Children's
-
-
Minnesota
-
Burnsville, Minnesota, Stati Uniti, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Mercy Hospital
-
Edina, Minnesota, Stati Uniti, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Stati Uniti, 55432
- Unity Hospital
-
Maplewood, Minnesota, Stati Uniti, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Stati Uniti, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Abbott-Northwestern Hospital
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stati Uniti, 55102
- United Hospital
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Chesterfield, Missouri, Stati Uniti, 63017
- Saint Luke's Hospital
-
City of Saint Peters, Missouri, Stati Uniti, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Stati Uniti, 63141
- Siteman Cancer Center at West County Hospital
-
Kansas City, Missouri, Stati Uniti, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Stati Uniti, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Stati Uniti, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Stati Uniti, 63141
- Mercy Hospital Saint Louis
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Stati Uniti, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Reno, Nevada, Stati Uniti, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Stati Uniti, 07920
- Memorial Sloan Kettering Basking Ridge
-
Hackensack, New Jersey, Stati Uniti, 07601
- Hackensack University Medical Center
-
Middletown, New Jersey, Stati Uniti, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Stati Uniti, 07645
- Memorial Sloan Kettering Bergen
-
Morristown, New Jersey, Stati Uniti, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Rutgers Cancer Institute of New Jersey
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Paterson, New Jersey, Stati Uniti, 07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- Presbyterian Hospital
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Albany Medical Center
-
Buffalo, New York, Stati Uniti, 14263
- Roswell Park Cancer Institute
-
Commack, New York, Stati Uniti, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Stati Uniti, 10604
- Memorial Sloan Kettering Westchester
-
New Hyde Park, New York, Stati Uniti, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stati Uniti, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Stati Uniti, 10065
- NYP/Weill Cornell Medical Center
-
Rochester, New York, Stati Uniti, 14642
- University of Rochester
-
Stony Brook, New York, Stati Uniti, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Stati Uniti, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center - Moses Campus
-
Uniondale, New York, Stati Uniti, 11553
- Memorial Sloan Kettering Nassau
-
Valhalla, New York, Stati Uniti, 10595
- New York Medical College
-
Webster, New York, Stati Uniti, 14580
- Wilmot Cancer Institute at Webster
-
-
North Carolina
-
Asheville, North Carolina, Stati Uniti, 28801
- Mission Hospital
-
Asheville, North Carolina, Stati Uniti, 28803
- AdventHealth Infusion Center Asheville
-
Charlotte, North Carolina, Stati Uniti, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Stati Uniti, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Stati Uniti, 27834
- East Carolina University
-
Hendersonville, North Carolina, Stati Uniti, 28792
- AdventHealth Hendersonville
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Stati Uniti, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Stati Uniti, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Stati Uniti, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Stati Uniti, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Stati Uniti, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Stati Uniti, 45404
- Dayton Children's Hospital
-
Dayton, Ohio, Stati Uniti, 45415
- Dayton Physician LLC - Englewood
-
Kettering, Ohio, Stati Uniti, 45429
- Kettering Medical Center
-
Kettering, Ohio, Stati Uniti, 45409
- Greater Dayton Cancer Center
-
Toledo, Ohio, Stati Uniti, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health and Science University
-
Portland, Oregon, Stati Uniti, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Stati Uniti, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Stati Uniti, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Columbia, South Carolina, Stati Uniti, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Stati Uniti, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Stati Uniti, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Stati Uniti, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Stati Uniti, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Stati Uniti, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Stati Uniti, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Stati Uniti, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Amarillo, Texas, Stati Uniti, 79106
- Texas Tech University Health Sciences Center-Amarillo
-
Austin, Texas, Stati Uniti, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Stati Uniti, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Stati Uniti, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Stati Uniti, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Stati Uniti, 79905
- El Paso Children's Hospital
-
Houston, Texas, Stati Uniti, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Stati Uniti, 77030
- Houston Methodist Hospital
-
Houston, Texas, Stati Uniti, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Stati Uniti, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Stati Uniti, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Stati Uniti, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Stati Uniti, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Stati Uniti, 78229
- Methodist Children's Hospital of South Texas
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84113
- Primary Children's Hospital
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, Stati Uniti, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Stati Uniti, 23507
- Children's Hospital of The King's Daughters
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Stati Uniti, 24014
- Carilion Children's
-
-
Washington
-
Renton, Washington, Stati Uniti, 98055
- Valley Medical Center
-
Seattle, Washington, Stati Uniti, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Stati Uniti, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Stati Uniti, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Stati Uniti, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Charleston, West Virginia, Stati Uniti, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center-Marshfield
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Age >= 2 years
-
Patient must have histologically confirmed primary mediastinal B-cell lymphoma (PMBCL) as defined by World Health Organization (WHO) criteria
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 or ECOG performance status of 3 if poor performance is related to lymphoma
- Children's Oncology Group (COG) Institutions: Use Karnofsky for patients >= 17 and < 18 years of age and Lansky for patients < 17 years of age
-
Adults (age 18 or older): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight
-
Pediatric Patients (age < 18 years): The following must have been obtained within 14 days prior to registration:
-
Measured or calculated (based on institutional standard) creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2, or
-
Serum creatinine =< 1.5 x institutional upper limit of normal (IULN), or a serum creatinine based on age/sex as follows:
- Age : 2 to < 6 year; Maximum serum creatinine (mg/dL): 0.8 (male; 0.8 (female)
- Age : 6 to < 10 years; Maximum serum creatinine (mg/dL): 1 (male); 1 (female)
- Age : 10 to < 13 years; Maximum serum creatinine (mg/dL): 1.2 (male); 1.2 (female)
- Age : 13 to < 16 years; Maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)
- Age : >= 16 years to < 18 years; Maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female)
-
-
Patients with abnormal liver function will be eligible to enroll if the lab abnormality is thought to be due to the lymphoma or Gilbert's syndrome
-
Age >= 18 years: Ejection fraction of >= 50% by echocardiogram
-
Age < 18 years: Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Administration of prior anti-cancer therapy except as outlined below:
- A short course (=< 2 weeks) of corticosteroids for the relief of lymphoma-related symptoms
- A single course of COP (cyclophosphamide, vincristine, and prednisone)
- One cycle of chemo-immunotherapy including R-CHOP, DA-EPOCH-R, a pediatric mature B-cell non-Hodgkin lymphoma (B-NHL) induction therapy (such as ANHL1131), or intrathecal chemotherapy that has not started more than 21 days prior to enrollment
-
Active ischemic heart disease or heart failure
-
Active uncontrolled infection
-
Central nervous system (CNS) involvement of lymphoma
-
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this trial
-
Active autoimmune disease that has required systemic treatment (such as disease modifying agents, corticosteroids, or immunosuppressive agents) in the past 2 years. Replacement therapy such as thyroxine, insulin or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment
-
In patients < 18 years of age hepatitis B serologies consistent with past or current infections
-
Patients with severe hepatic impairment (Child-Pugh class C or serum total bilirubin > 5.0 mg/dL) unless thought to be due to lymphoma or Gilbert's syndrome
-
Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
-
Sexually active patients of reproductive potential who have not agreed to use a highly effective contraceptive method (failure rate of < 1% per year when used consistently and correctly) for the duration of their study participation
-
Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy and for at least 6 months after the last dose of rituximab
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Arm A (DA-EPOCH-R)
See Detailed Description |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo CT or PET/CT
Altri nomi:
Undergo PET/CT
Altri nomi:
Given IV
Altri nomi:
Given SC
Altri nomi:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Altri nomi:
Given PO
Altri nomi:
Given SC
Altri nomi:
Undergo LP
Altri nomi:
Undergo blood and CSF sample collection
Altri nomi:
Given SC
Altri nomi:
|
|
Sperimentale: Arm B (DA-EPOCH-R, nivolumab)
Patients receive treatment as in Arm A. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and LP for CSF collection during screening. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Given IV
Altri nomi:
Undergo CT or PET/CT
Altri nomi:
Undergo PET/CT
Altri nomi:
Given IV
Altri nomi:
Given SC
Altri nomi:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Altri nomi:
Given PO
Altri nomi:
Given SC
Altri nomi:
Undergo LP
Altri nomi:
Undergo blood and CSF sample collection
Altri nomi:
Given SC
Altri nomi:
|
|
Comparatore attivo: Arm C (R-CHOP)
Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 1-15 minutes or up to 60 minutes, and vincristine sulfate IV over 1 or up to 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo CT or PET/CT
Altri nomi:
Undergo PET/CT
Altri nomi:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Altri nomi:
Given PO
Altri nomi:
Undergo LP
Altri nomi:
Undergo blood and CSF sample collection
Altri nomi:
Given SC
Altri nomi:
|
|
Sperimentale: Arm D (R-CHOP, nivolumab)
Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Given IV
Altri nomi:
Undergo CT or PET/CT
Altri nomi:
Undergo PET/CT
Altri nomi:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Altri nomi:
Given PO
Altri nomi:
Undergo LP
Altri nomi:
Undergo blood and CSF sample collection
Altri nomi:
Given SC
Altri nomi:
|
|
Comparatore attivo: Arm E (R-CHOP, radiation therapy)
Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo CT or PET/CT
Altri nomi:
Undergo PET/CT
Altri nomi:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Altri nomi:
Undergo radiation therapy
Altri nomi:
Given PO
Altri nomi:
Undergo LP
Altri nomi:
Undergo blood and CSF sample collection
Altri nomi:
Given SC
Altri nomi:
|
|
Sperimentale: Arm F (R-CHOP, nivolumab, radiation therapy)
Patients receive treatment as in Arm D. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given PO
Altri nomi:
Given IV
Altri nomi:
Undergo ECHO
Altri nomi:
Given IV
Altri nomi:
Undergo CT or PET/CT
Altri nomi:
Undergo PET/CT
Altri nomi:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Altri nomi:
Undergo radiation therapy
Altri nomi:
Given PO
Altri nomi:
Undergo LP
Altri nomi:
Undergo blood and CSF sample collection
Altri nomi:
Given SC
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free survival (PFS)
Lasso di tempo: From enrollment on the study to first occurrence of relapse/progression or death, assessed up to 7 years
|
The primary analysis will be a one-sided Log-rank test stratified by choice of backbone and radiation therapy and whether the patient had a cycle of therapy prior to enrolling. |
From enrollment on the study to first occurrence of relapse/progression or death, assessed up to 7 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Efficacy-related event-free survival
Lasso di tempo: Up to 7 years
|
Will be analyzed using a one-sided stratified Log-rank test at alpha = 0.05 or 0.025, as appropriate, with events defined as progression, change in therapy due to a finding that led to concern about efficacy, biopsy + disease after 6 cycles of therapy, and death. |
Up to 7 years
|
|
Therapy-related event-free survival
Lasso di tempo: Up to 7 years
|
Will be analyzed using a one-sided stratified Log-rank test at alpha = 0.05 or 0.025, as appropriate, with events defined as progression, change in therapy due to a finding that led to concern about efficacy, biopsy + disease after 6 cycles of therapy, and death. |
Up to 7 years
|
|
Overall survival
Lasso di tempo: Up to 7 years
|
Will be analyzed using a one-sided stratified Log-rank test at alpha = 0.05 or 0.025, as appropriate, with events defined as only death. |
Up to 7 years
|
|
Proportion of positive positron emission tomography (PET) scans
Lasso di tempo: Up to 6 cycle (1 cycle = 21 days)
|
Will be analyzed descriptively with a point estimate and Clopper-Pearson 95% confidence interval in the trial overall and in each treatment arm separately. The prognostic significance of positive PET after 6 cycles of therapy will be evaluated using a Cox proportional hazards regression on PFS with PET result (positive versus [vs.] negative), choice of backbone (rituximab [R]-cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] + radiation therapy [RT] regardless of end-of-therapy imaging vs. R-CHOP without RT unless biopsy positive at end-of-therapy vs. dose-adjusted [DA]-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin [EPOCH]-R without RT unless biopsy positive at end of therapy), and assignment to nivolumab (yes vs. no) as covariates. |
Up to 6 cycle (1 cycle = 21 days)
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Immune profile of patients treated with nivolumab + chemo-immunotherapy
Lasso di tempo: Up to 7 years
|
Analysis will be by paired t-test (for pre- vs. post-treatment measurements) or two-sample equal-variance t-test (for comparisons of nivolumab vs. non-nivolumab or responders [complete response/partial response] vs. non-responders [stable disease/progressive disease]). |
Up to 7 years
|
|
Complete response rate
Lasso di tempo: At the completion of initial planned therapy
|
Will be described using point estimates and Clopper-Pearson 95% confidence intervals for the complete response rate overall and in each treatment arm separately. |
At the completion of initial planned therapy
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Lisa G Roth, Children's Oncology Group
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Peptidi
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Tecniche investigative
- Terapie
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Forature
- Procedure chirurgiche, operative
- Tecniche citologiche
- Citodiagnosi
- Idrocarburi
- Idrocarburi, ciclici
- Fattori biologici
- Carboidrati
- Fenomeni fisici
- Alcaloidi
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glicosidi
- Glicoside idrolasi
- Idrolasi
- Enzimi
- Enzimi e coenzimi
- Polisaccaride-Laryases
- Liasi di ossigeno carbonio
- Lyasi
- Indoli
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Tecniche diagnostiche, chirurgiche
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Peptidi e proteine di segnalazione intercellulare
- Incintadienetrioli
- Incintadienediols
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Antracicline
- Naftaceni
- Aminoglicosidi
- Glicoproteine
- Glicoconiugati
- Anticorpi, monoclonali, derivati da murina
- Daunorubicina
- Tecniche diagnostiche, neurologiche
- Fattori stimolanti le colonie
- Fattori di crescita delle cellule ematopoietiche
- Citochine
- Nivolumab
- Rituximab
- Prednisone
- Prednisolone
- Ciclofosfamide
- Doxorubicina
- Vincristina
- Metilprednisolone
- Radioterapia
- Ialuronoglucosaminidasi
- Radiazione
- Biopsia
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Puntura spinale
- CT-P10
- Fattore stimolante le colonie di granulociti
- Filgrastim
- Deltacorne
- Prednylidene
- pegfilgrastim
- etoposide fosfato
- fattore stimolante le colonie di granulociti
Altri numeri di identificazione dello studio
- NCI-2021-01071
- U10CA180886 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2021-01071 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- ANHL1931 (Altro identificatore: CTEP)
- ANHL1931 (Altro identificatore: Children's Oncology Group)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .